Status:
UNKNOWN
Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Trauma
Brain Injuries
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Beta blockers (BB) play an important role in protection of end organs that are susceptible for secondary injury by the Traumatic brain injury (TBI)-induced catecholamine surge. However, use of BBs in ...
Detailed Description
Traumatic brain injury (TBI) accounts for up to 30% of all injury-related deaths \[1\]. It also poses a significant morbidity and economic burden world-wide \[2,3\]. While there has been significant a...
Eligibility Criteria
Inclusion
- All adults (≥18 -65 years)
- both genders
- mild-to-severe blunt TBI (head AIS 1-5 and/ GCS 4-15) patients requiring hospital admission
Exclusion
- Patients \<18 and\> 65 yrs old
- penetrating trauma
- non-survivable injuries (head AIS=6 \& GCS=3)
- uncontrolled bleeding on arrival to ED
- pregnant women
- prisoners
- patients with heart rate (HR) ≤70, systolic blood pressure (SBP) ≤100 mmHg (or MAP \<70 mmHg) not responding to initial management or required to be maintained on vasopressors on arrival .
- Patients who will undergo hypothermia therapy,
- any penetrating injury to head, thorax or abdomen,
- history of bronchial asthma
- patients posted for emergency surgery during the first 6 hrs.
Key Trial Info
Start Date :
December 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
771 Patients enrolled
Trial Details
Trial ID
NCT04508244
Start Date
December 29 2020
End Date
December 31 2024
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad General Hospital
Doha, Qatar